Dr Vali / BDV sleep peptide protocol: DSIP + Selank + Epithalon
Poor sleep is not just tiredness. It is a biological breakdown of mood, metabolism, memory, immunity, and longevity. At BDV, we treat sleep as a system, not a symptom. Our peptide stacking protocol uses DSIP, Selank, and Epithalon to restore circadia...
The diagnosis is right and the prescription is theater. Framing sleep as a system, not a symptom, is genuinely good — but the response shouldn't be three obscure peptides with thin human evidence and no disclosed doses. CBT for insomnia, sleep apnea screening, and basic sleep hygiene out-evidence DSIP / Selank / Epithalon by orders of magnitude, are usually free, and don't require a clinic injection. Epithalon as the longevity hook is the giveaway.
| Goal | Score | Grade | Weight | Why |
|---|---|---|---|---|
| Longevity | 67 | D+ | 20% | Epithalon is the longevity hook, but the human evidence base is essentially one Russian research group's older work and hasn't been replicated by modern, independent trials. |
| Cognition | 70 | C- | 10% | Selank has anxiolytic/nootropic data from Russian clinical literature; the mechanism is real even if Western replication is thin. |
| Sleep & recovery | 71 | C- | 70% | The targeted axis, but the protocol skips the highest-evidence first-line interventions (CBT-i, sleep hygiene, apnea screening) in favor of three peptides whose human RCT support for sleep is anecdotal at best. |
| Energy & metabolism | — | Not targeted | — | No ingredient in the stack has a direct metabolic mechanism. |
| Body recomposition | — | Not targeted | — | No anabolic agent or training stimulus in the protocol. |
Ingredients (3)
DSIP
- Dose
- unspecified
- Mechanism
- Nonapeptide first isolated from rabbit brain in the 1970s; proposed to modulate non-REM sleep depth and stress response, possibly via opioid-system and HPA-axis interactions. Mechanism is incompletely characterized.
- Take
- DSIP has been studied since the 1970s, mostly in animals and a handful of small human trials in chronic insomnia and stress. The compound has never gotten past early-stage research because effects in larger human studies haven't held up. Marketing it as a sleep peptide in 2026 is more about novelty than evidence — and BDV doesn't disclose a per-dose specification anyway.
Selank
- Dose
- unspecified
- Mechanism
- Synthetic heptapeptide based on tuftsin; proposed anxiolytic and nootropic effects via GABA-A receptor modulation and BDNF expression. Studied primarily in Russian clinical literature.
- Take
- Selank has more human data than DSIP — but almost all of it from Russian clinical research that hasn't been replicated in Western RCTs. Intranasal use at 75–250mcg/day is the published range. Anxiolytic effects could plausibly help anxious-pattern insomnia, but framing it as a sleep peptide specifically is a stretch.
Epithalon
Epithalon on peptidelist.org ↗
- Dose
- unspecified
- Mechanism
- Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from epithalamin, a pineal extract; claimed to upregulate telomerase, restore melatonin secretion, and normalize circadian rhythms in older adults.
- Take
- Epithalon's evidence base is essentially the Khavinson group at the St Petersburg Institute of Bioregulation and Gerontology — published in venues that haven't been replicated by modern, independent, well-controlled trials. Telomerase claims are particularly thin. As a sleep stack ingredient, it's more longevity-marketing than circadian medicine.
Risks & interactions
- Clinic protocol with no disclosed doseshigh
The tweet describes a 'protocol' without a single dose. For a clinic offering injections, that's a fundamental information gap — patients can't compare protocols, evaluate published-dose alignment, or recognize when their dose is being adjusted. The same pattern that makes vendor blends untrustworthy applies to clinic protocols that don't publish dosing.
- Three peptides with weak independent evidence; zero combinatorial datahigh
Each peptide individually has thin human evidence; their combination has essentially none. There are no published RCTs of DSIP + Selank + Epithalon in any indication. 'Stacking protocol' is operative because the marketing language is real — but the empirical support for stacking these three together for sleep isn't.
- First-line evidence-based sleep interventions skippedmedium
For chronic insomnia, the highest-evidence intervention is CBT-i (cognitive behavioral therapy for insomnia), followed by sleep hygiene, sleep apnea screening, and underlying-cause workup. None of these are mentioned. A peptide-first protocol for sleep skips the modalities that actually work for most people in favor of ones that mostly don't.
- Compounded research peptides regulatory grey zonemedium
DSIP, Selank, and Epithalon are not FDA-approved for any indication in the US. Clinic use typically routes through compounding pharmacies or research-chemical sourcing, with the same purity, sterility, and labeling concerns that apply to research-vendor peptides. A clinic context doesn't automatically resolve those.
- 'Restore circadian' framing is mechanistically vaguelow
Real circadian dysfunction has measurable phenotypes (DLMO timing, core body temperature rhythm, melatonin profile). The only stack ingredient with a circadian-specific mechanism (Epithalon → pineal/melatonin) has the weakest evidence base of the three. Light therapy, fixed wake times, and properly timed melatonin have stronger circadian-specific evidence and aren't mentioned.
CBT-i out-evidences DSIP / Selank / Epithalon by orders of magnitude for chronic insomnia, costs $0–600 once (not $400–1200/month indefinitely), and is the actual standard of care. A clinic that frames sleep as 'a system, not a symptom' should be screening for sleep apnea and routing patients to CBT-i first; if the peptides are ever warranted, they're a third-line tool, not the headline protocol.
Estimated cost
Typical US compounding-pharmacy peptide clinic monthly cost for a 3-peptide injectable protocol is $400–1200, depending on dosing frequency and clinic markup. BDV's specific pricing is not in the source tweet.